Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 7/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 5/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 4/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469769 | 0.81 | PLAU (0.41) | PLAUF2PRSS1KITFLT3 | |
| SCHEMBL17469775 | 0.78 | F2 (0.49) | PLAUF2ST14PRSS1PRSS2 | |
| SCHEMBL19006228 | 0.70 | PLAU (0.40) | PLAUF2F10HDAC1HDAC6 | |
| SCHEMBL17469772 | 0.69 | PLAU (0.49) | PLAUF2ST14PRSS1PRSS2 | |
| SCHEMBL17469777 | 0.65 | KCNJ11 (0.44) | PLAUF2PRSS1KITFLT3 | |
| SCHEMBL17469791 | 0.62 | WDR5 (0.49) | PLAUF2PRSS1KITFLT3 | |
| SCHEMBL17469787 | 0.62 | WDR5 (0.45) | PLAUF2PRSS1PRSS3KIT | |
| SCHEMBL17469783 | 0.60 | FLT3 (0.52) | PLAUF2ST14PRSS1PRSS2 | |
| SCHEMBL17469647 | 0.60 | KIT (0.70) | PLAUF2ST14PRSS1KIT | |
| SCHEMBL17469786 | 0.60 | WDR5 (0.41) | PLAUF2PRSS1KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | PLAU 3225/4885F2 4544/4885PIN1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.